Home › Funds › Bratton Capital Management, L.P. › AQST
Bratton Capital Management, L.P. position in AQST
AQUESTIVE THERAPEUTICS INC · Health Care
Bratton Capital Management, L.P. reported holding 9,810,958 shares of AQST (AQUESTIVE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$45.4M, representing 100.00% of its reported portfolio and ranking #1 among its reported holdings. Bratton Capital Management, L.P. has disclosed AQST holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Bratton Capital Management, L.P.'s AQST position evolved
Bratton Capital Management, L.P. first disclosed a stake in AQST in Q3 2023 at 9,810,958 shares (US$1.50B). Across 13 filings, Bratton Capital Management, L.P. held the position steady without any share-count change. The most recent filing (Q3 2026) shows 9,810,958 shares valued at US$45.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 9.81M | $1.50B | New |
| Q4 2023 | 9.81M | $19.82M | Hold |
| Q1 2024 | 9.81M | $41.79M | Hold |
| Q2 2024 | 9.81M | $25.51M | Hold |
| Q3 2024 | 9.81M | $48.86M | Hold |
| Q4 2024 | 9.81M | $34.93M | Hold |
| Q1 2025 | 9.81M | $28.45M | Hold |
| Q2 2025 | 9.81M | $32.47M | Hold |
| Q3 2025 | 9.81M | $54.84M | Hold |
| Q4 2025 | 9.81M | $63.38M | Hold |
| Q1 2026 | 9.81M | $40.72M | Hold |
| Q2 2026 | 9.81M | $40.81M | Hold |
| Q3 2026 | 9.81M | $45.42M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AQST and 13F data
AQST (AQUESTIVE THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in AQST — the largest reported positions include Samsara BioCapital, LLC (US$10.4M), Propel Bio Management, LLC (US$8.6M), Blue Owl Capital Holdings LP (US$6.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AQST
- Samsara BioCapital, LLC 2.50M sh · $10.40M · Q2 2026
- Propel Bio Management, LLC 278.72K sh · $8.61M · Q3 2026
- Blue Owl Capital Holdings LP 1.39M sh · $6.44M · Q3 2026
- Sio Capital Management, LLC 1.49M sh · $6.18M · Q2 2026
- DAFNA Capital Management LLC 645.91K sh · $2.69M · Q2 2026
- Everstar Asset Management, LLC 611.94K sh · $2.55M · Q2 2026
- Bracebridge Capital, LLC 459.22K sh · $1.91M · Q2 2026
More on Bratton Capital Management, L.P.
FAQ
How long has Bratton Capital Management, L.P. held AQST?
Bratton Capital Management, L.P. has disclosed AQST holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Bratton Capital Management, L.P.'s current position in AQST?
As of Q3 2026, Bratton Capital Management, L.P. holds 9.81M shares of AQST (AQUESTIVE THERAPEUTICS INC), valued at $45.42M, representing 100.00% of its reported portfolio and ranking #1.
Has Bratton Capital Management, L.P. been buying or selling AQST?
In the latest 13F filing (Q3 2026), Bratton Capital Management, L.P. held unchanged its position in AQST.
Which other funds hold AQST?
Other major institutional holders of AQST include Samsara BioCapital, LLC, Propel Bio Management, LLC, Blue Owl Capital Holdings LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.